



# Salivary *Streptococcus mutans* and Lactobacilli Levels as Indicators of Dental Caries Development in Iranian Patients with Systemic Sclerosis

Sepideh Najafi<sup>1</sup>, Maryam Mardani<sup>2\*</sup> , Mohammad Motamedifar<sup>3</sup> ,  
Mohammad Ali Nazarinia<sup>4</sup> , Mahtab Hadadi<sup>5</sup>

1. Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
2. Oral and Dental Disease Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Medical Microbiology, Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
4. Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5. Department of Bacteriology and Virology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

## ABSTRACT

**Background and Aim:** Systemic sclerosis is an autoimmune disorder with orofacial manifestations, including tooth decay. Lactobacilli can inhibit biofilm formation and growth of cariogenic pathogens, such as *Streptococcus mutans*. We aimed to assess the salivary levels of *S. mutans* and Lactobacilli as indicators of dental caries development in patients with systemic sclerosis.

**Materials and Methods:** In this cross-sectional study, 80 patients with systemic sclerosis were assigned into 2 groups, anti-centromere antibody (ACA) positive (n=42) and ACA-negative (n=38). Besides, 80 age- and gender-matched healthy individuals were enrolled as control. Unstimulated saliva was collected in sterile tubes. Blood agar and tomato juice agar were used to cultivate *S. mutans* and Lactobacilli. The number of colony-forming units per milliliter (CFU/mL) was calculated and compared between the groups.

**Results:** *S. mutans* in patients (median=1.6×10<sup>7</sup> CFU/mL; interquartile range (IQR): 1.1–3.1 ×10<sup>7</sup> CFU/mL) was significantly higher than control group (median=5.1×10<sup>6</sup> CFU/mL; IQR: 5.1–7.9 ×10<sup>6</sup> CFU/mL) ( $P<0.0001$ , Mann-Whitney U-test); however, the median Lactobacilli levels was similar between these groups (3.4×10<sup>6</sup> vs. 2.2×10<sup>6</sup> CFU/mL;  $P=0.095$ ). The median concentrations of *S. mutans* (1.3×10<sup>7</sup> vs. 2.4×10<sup>7</sup> CFU/mL;  $P=0.342$ ) and Lactobacilli (4.1×10<sup>6</sup> CFU/mL vs. 3.1×10<sup>6</sup> CFU/mL;  $P=0.515$ ) in the ACA-positive and ACA-negative patients had no significant differences. There were no significant correlation coefficients between *S. mutans* and Lactobacilli levels in the study groups ( $P>0.05$ ).

**Conclusion:** Our findings suggest the higher levels of salivary *S. mutans* in patients with systemic sclerosis might increase the likelihood of dental caries over time; however, it was not affected by the ACA status.

**Keywords:** Lactobacilli, Saliva, *Streptococcus mutans*, Systemic sclerosis

Received: 2021/09/25;

Accepted: 2022/03/05;

Published Online: 2022/05/25

### Corresponding Information:

Maryam Mardani, Oral and Dental Disease Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran  
Email: [mardanim@sums.ac.ir](mailto:mardanim@sums.ac.ir)



Copyright © 2021, This is an original open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits copy and redistribution of the material just in noncommercial usages with proper citation.



Use your device to scan and read the article online

Mardani M, Najafi S, Motamedifar M, Nazarinia M A, Hadadi M. Salivary *Streptococcus mutans* and Lactobacilli Levels as Indicators of Dental Caries Development in Iranian Patients with Systemic Sclerosis. Iran J Med Microbiol. 2022; 16 (4) :350-356

Download citation: [BibTeX](#) | [RIS](#) | [EndNote](#) | [Medlars](#) | [ProCite](#) | [Reference Manager](#) | [RefWorks](#)

Send citation to:  [Mendeley](#)  [Zotero](#)  [RefWorks](#)

## 1 Introduction

Systemic sclerosis, also known as scleroderma, is a rare chronic autoimmune disorder of connective tissue characterized by the progressive fibrosis of the skin and several internal organs (1, 2). It is divided into diffuse cutaneous and limited cutaneous forms based

on the extent of skin involvement. The peak incidence of systemic sclerosis is in the fifth decade of life and tends to affect women more than men. The exact etiology of the disease remains uncertain; however, a wide range of genetic, infectious, and environmental

factors are thought to contribute to the development of systemic sclerosis (2-5).

Antinuclear antibodies (ANA), such as anti-topoisomerase I antibody (ATA), anti-centromere antibody (ACA), and anti-RNA polymerase III antibody (ARA), are the hallmarks of immune dysregulation and are frequently detected in patients with systemic sclerosis. They are helpful for the early diagnosis of the disease and are established as strong predictors of disease outcome (6-8). Among autoantibodies, ACA is most commonly associated with systemic sclerosis, is useful in classifying systemic sclerosis variants, and often remains stable during disease. Positivity for ACA has been associated with a higher survival rate (9-11). Currently, there is no proven curative therapy for systemic sclerosis and it still poses a great challenge to clinicians (12, 13).

Patients with systemic sclerosis are at a higher risk for dental caries than the general population due to reduced mouth opening, salivary hypofunction, xerostomia, impaired oral hygiene, immunosuppression, bone resorption, and the pronounced dysfunction of hand joints (14-18). Chu *et al.* (19) showed that Chinese people with systemic sclerosis had caries experience (DMFT=10.5), as well as lower resting salivary flow and pH values. *Streptococcus mutans* (*S. mutans*) is a gram-positive facultative anaerobic pathogen, the natural habitat of which is the oral cavity of humans. It is an acidogenic bacterium with the ability to form biofilm on tooth surfaces, known as dental plaque. *S. mutans* can secrete water-insoluble glucans in a sucrose-containing environment that enhances bacterial adhesion to the tooth surface. Consequently, bacterial co-aggregation leads to the development of highly virulent mixed-species biofilms in the oral cavity. Scientific evidence revealed that *S. mutans* is a primary pathogen and central facilitator of dental caries and decay lesions in the early stages mainly due to the irreversible dissolution of enamel minerals (20-22). On the other hand, probiotic bacteria have shown several health benefits to the host because of modifying the microbiome. Some probiotic strains can interfere with the biofilm formation of cariogenic bacteria, such as *S. mutans* (23-25). *Lactobacilli* strains are the most common probiotics found in commercial dental products, which potently reduce the growth of *S. mutans* and inhibit the biofilm formation of this cariogenic bacterium. However, little is known about the effects of *Lactobacilli* species on dental caries (26-28).

The salivary *S. mutans* and *Lactobacilli* enumeration may be considered a reflection of the oral health of an individual. Moreover, they are closely associated with the development of dental caries. Therefore, the current study was designed to assess the salivary

levels of these bacteria to find whether naturally occurring *S. mutans* and *Lactobacilli* are related to systemic sclerosis.

## 2. Materials and Methods

### Ethical Considerations

Prior to any experiment, written informed consent was obtained from all participants in accordance with the Declaration of Helsinki and its later amendment. The study protocol was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (IR.SUMS.DENTAL.REC.1399.096).

### Study Design

This cross-sectional study was performed on 80 patients with a confirmed diagnosis of systemic sclerosis who were routinely visited in the Rheumatology Clinic of Hafez Hospital affiliated with Shiraz University of Medical Sciences, Iran, during August 2020-September 2020. Systemic sclerosis was diagnosed by a rheumatologist according to the criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Based on the medical records, patients were assigned into two groups ACA-positive (N=42) and ACA-negative (N=38).

The inclusion criteria were adult age, good general health, and not having used any antibiotics, chlorhexidine, sodium fluoride, or probiotic mouthwashes for 4 weeks before the study. Patients with systemic disorders, diabetes, oral breathing, chronic periodontitis, gingivitis, other autoimmune diseases rather than systemic sclerosis, and any medical conditions that could interfere with the study were excluded. All patients were referred to the dental specialized clinic affiliated with Shiraz University of Medical Sciences, Iran. Clinical oral health status was assessed for each patient by a single dentist examiner. The DMFT index for decayed, missing, and filled teeth was determined using the standard methods suggested by World Health Organization. In addition, the control group of this study consisted of 80 healthy individuals without any systemic and/or autoimmune diseases who were matched with the patients group in terms of age, gender, and DMFT index.

Two hours prior to sampling, all participants were requested to perform a thorough tooth-brushing and refrain from food and drink consumption. Unstimulated whole saliva sample (5 mL) was self-collected by each participant. During salivation, the study subjects were requested to keep their eyes open, avoid movements and speaking, and mentally stimulate salivary flow as far as possible. Collected

saliva samples were sent immediately to the laboratory for microbiological analyses.

### Microbiological Assessments

Before plating, 100  $\mu\text{L}$  of saliva sample was diluted with 1.9 mL of sterile water. Next, the aliquots of the suspension (50  $\mu\text{L}$ ) were directly spread on blood agar (Merck, Germany) and tomato juice agar (Merck, Germany) plates to isolate salivary *S. mutans* or *Lactobacilli*, respectively. Afterwards, plates were sealed, placed in an anaerobic jar, and incubated at 37°C for 48 h. Morphological characteristics of colonies were assessed. Colonies on solid plates were characterized by gram staining, catalase, biochemical tests, and resistance to bacitracin and optochin. Colony counting for each specimen was performed by 100-folds dilution with saline and then, 10  $\mu\text{L}$  of each sample was transferred to the colony plates. The plates were set in microaerophilic conditions and were incubated for 1 day at 37°C. Finally, the colonies were counted using the Quebec colony counter (Reichert, USA), multiplied by the dilution factor, and expressed as the number of colony-forming units per milliliter (CFU/mL) of saliva. All bacteriological analyses were commenced within 2 h of sampling and were performed by a single-blinded expert microbiologist in three replicates.

### Statistical Analysis

Statistical analyses were carried out using the IBM SPSS Statistics for Windows version 22 (IBM, Armonk, NY, USA). The normality of data distribution was checked using the Shapiro-Wilk test. Data with non-normal distribution were presented as the median and interquartile range (IQR). The Mann-Whitney U test was used to examine the differences between the study groups. Furthermore, the correlation between salivary *S. mutans* and *Lactobacilli* was evaluated utilizing the Pearson correlation coefficient test.  $P$ -value < 0.05 was considered statistically significant.


## 3. Results

The patients group consisted of 74 women and 6 men with an average age of 50.7 $\pm$ 11.2 years. Out of

the 80 subjects in the control group, 92.5% were female (N=74) and 7.5% were male (N=6) with a mean age of 52.2 $\pm$ 9.1 years. There were no significant differences between the case and control groups in terms of gender ( $P=1$ ) and age ( $P=0.465$ ). Moreover, two subgroups of systemic sclerosis, namely ACA-positive (N=42) and ACA-negative (N=38) patients were not significantly different in gender ( $P=0.527$ ) and age ( $P=0.356$ ). There were no statistically significant differences ( $P>0.05$ ) in the mean DMFT values of patients and control groups, as well as the ACA-positive and ACA-negative subjects.

*S. mutans* and *Lactobacilli* were detected in 100% of unstimulated saliva samples collected from the case and control groups, and there were no missing data. However, the Mann-Whitney U-test demonstrated statistically significant differences between the study groups. The median salivary concentration of *S. mutans* in patients with systemic sclerosis ( $1.6\times 10^7$  CFU/mL; IQR:  $1.1$ - $3.1\times 10^7$  CFU/mL) was significantly higher than in the control group ( $5.1\times 10^6$  CFU/mL; IQR:  $5.1$ - $7.9\times 10^6$  CFU/mL) ( $P<0.0001$ ). However, *Lactobacilli* levels were similar between patients ( $3.4\times 10^6$  CFU/mL; IQR:  $1.6$ - $11.6\times 10^6$  CFU/mL) and control subjects ( $2.2\times 10^6$  CFU/mL; IQR:  $1.2$ - $8.1\times 10^6$  CFU/mL) ( $P=0.095$ ).

As shown in [Figure 1](#), the median salivary concentration of *S. mutans* in the ACA-positive ( $1.3\times 10^7$  CFU/mL; IQR:  $1.1$ - $3.1\times 10^7$  CFU/mL) and ACA-negative ( $2.4\times 10^7$  CFU/mL; IQR:  $1.1$ - $3.1\times 10^7$  CFU/mL) subjects was not significantly different ( $P=0.342$ ). In addition, no significant difference was observed between the ACA-positive ( $4.1\times 10^6$  CFU/mL; IQR:  $1.5$ - $13.1\times 10^6$  CFU/mL) and ACA-negative ( $3.1\times 10^6$  CFU/mL; IQR:  $1.3$ - $11.4\times 10^6$  CFU/mL) groups in terms of *Lactobacilli* count ( $P=0.515$ ). No significant correlation was detected between the salivary concentration of *S. mutans* and *Lactobacilli* in either patients ( $R=0.099$ ,  $P=0.38$ ) or control ( $R=0.186$ ,  $P=0.251$ ) groups. There were no significant differences between males and females regarding salivary *S. mutans* and *Lactobacilli* concentrations ( $P>0.05$ ).



**Figure 1.** The levels of *S. mutans* and *Lactobacilli* in unstimulated saliva samples

## 4. Discussion

Orofacial manifestations, including dental caries, are common in systemic sclerosis (5, 18, 19). Dental caries generally occurs in the presence of cariogenic bacteria and is a simple process in concept, but complicated in detail. The oral cavity contains a wide range of bacterial species, some of which have cariogenic properties (29). Previous studies reported that the oral microbiome can change in autoimmune disorders. Therefore, the detection and quantitation of bacterial species in the oral cavity are necessary to understand the disease process (30, 31). In this regard, the current study aimed to compare the total salivary levels of *S. mutans* and *Lactobacilli* between patients with systemic sclerosis and healthy individuals. Patients with systemic sclerosis were matched with the control group for DMFT index, gender, and age. Based on the findings of the present study, *S. mutans* and *Lactobacilli* were isolated from the unstimulated saliva samples of all participants. Higher levels of *S. mutans* and *Lactobacilli* were detected in the patients group.

Saliva is a non-invasive and easy-to-take sample, which is assumed to control the reproduction of microorganisms in the oral cavity. Stimulated saliva has been found to contain an estimated number of species over three times greater than unstimulated saliva (32). Therefore, we used unstimulated saliva to measure *S. mutans* and *Lactobacilli* levels. Systemic sclerosis is generally associated with the impairment of saliva production. Disease severity and duration play a crucial role in saliva secretion and pH values. Furthermore, patients with systemic sclerosis have decreased ability for brushing teeth as a result of sclerotic changes in the fingers and hands (5, 18, 19, 33-36). The immunosuppressive therapy commonly used in many autoimmune disorders, including systemic sclerosis, also creates a more permissive environment for oral pathogenic bacteria (14-17).

The current preliminary research was not specifically designed to evaluate these relationships in systemic sclerosis. We investigated the occurrence of hyposalivation/xerostomia, alterations in the pH of saliva, sclerotic changes, and immunosuppression, which can contribute to the growth of cariogenic bacteria and might in part explain the greater *S. mutans* levels observed in patients. Although the salivary levels of *S. mutans* and *Lactobacilli*, as well as their possible roles in caries development, have been assessed in different studies (33, 37-41), this issue has received no attention in systemic sclerosis.

Our data revealed that the salivary concentrations of *S. mutans* and *Lactobacilli* in ACA-positive and ACA-negative patients had no significant differences. The ACAs are most commonly associated with systemic

sclerosis (42). Moreover, they have also been reported in systemic lupus erythematosus, primary Raynaud's phenomenon, Rheumatoid arthritis, primary biliary cirrhosis, and Sjögren's syndrome. Baer *et al.* (9) found that ACA had an independent association with more severe exocrine glandular dysfunction and more pronounced labial salivary glandular inflammation. Consequently, dental practitioners should be aware of the potential systemic health problems related to tooth status in patients with systemic sclerosis and should periodically monitor such patients during the course of the disease.

The current study had a small sample size and potential unmeasured confounding. Ideally, patients in both genders with similar disease duration, activity, and severity would have been included for counting salivary *S. mutans* and *Lactobacilli* and investigating carries, but the enrollment of a sufficient number of such patients is difficult. On the other hand, the values obtained from a single saliva sample at one particular point of time could not well represent oral health status as dental caries develop over a considerable period, during which bacterial counts could fluctuate in response to the changing oral environment. Therefore, further comprehensive studies with a larger sample size that assess the dynamics of changes in salivary *S. mutans* and *Lactobacilli* during the progression of systemic sclerosis are warranted.

## 5. Conclusion

To the best of our knowledge, this paper is the first to assess the salivary levels of *S. mutans* and *Lactobacilli* in patients with systemic sclerosis. Our results support the hypothesis that total counts of salivary *S. mutans* in patients with systemic sclerosis is higher than in healthy individuals; however, the presence of anti-centromer antibodies could not have changed the amount of this cariogenic pathogen. Patients with systemic sclerosis should undergo regular dental check-ups to receive the proper preventive and restorative care and to detect potential issues before they worsen.

## Acknowledgment

The authors wish to thank Dr. Vossughi at Dental Research Development Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran, for the statistical analysis. This manuscript is based on a thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Dental Medicine by Sepideh Najafi.

## Ethics Approval

Prior to any experiment, written informed consent was obtained from each participant, in accordance with the Declaration of Helsinki and its later amendment. The study was conducted according to the protocol approved by the local Ethics Committee of the Shiraz University of Medical Science, Shiraz, Iran (IR.SUMS.DENTAL.REC.1399.096).

## Authors' Contribution

Study Design: Mardani M., Motamedifar M., Nazarinia M.A.

Collection of Data: Najafi S., Hadadi M., Motamedifar M., Nazarinia M.A.

## Reference

1. Hashempour A, Moayedi J, Musavi Z, Ghasabi F, Halaji M, Hasanshahi Z, et al. First report of HHV-8 viral load and seroprevalence of major blood-borne viruses in Iranian patients with systemic sclerosis. *Mult Scler Relat Disord*. 2021;51(2021):102872. [DOI:10.1016/j.msard.2021.102872] [PMID]
2. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. *Clin Rev Allergy Immunol*. 2017;53(3):306-36. [DOI:10.1007/s12016-017-8625-4] [PMID]
3. Stern EP, Denton CP. The Pathogenesis of Systemic Sclerosis. *Rheum Dis Clin North Am*. 2015;41(3):367-82. [DOI:10.1016/j.rdc.2015.04.002] [PMID]
4. Mayes MD. Scleroderma epidemiology. *Rheum Dis Clin North Am*. 2003;29(2):239-54. [DOI:10.1016/S0889-857X(03)00022-X]
5. Isola G, Williams RC, Lo Gullo A, Ramaglia L, Matarese M, Iorio-Siciliano V, et al. Risk association between scleroderma disease characteristics, periodontitis, and tooth loss. *Clin Rheumatol*. 2017;36(12):2733-41. [DOI:10.1007/s10067-017-3861-9] [PMID]
6. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. *Nat Rev Rheumatol*. 2010;6(2):112-6. [DOI:10.1038/nrrheum.2009.238] [PMID]
7. Domsic RT, Medsger TA. Autoantibodies and Their Role in Scleroderma Clinical Care. *Current Treatment Options in Rheumatology*. 2016;2(3):239-51. [DOI:10.1007/s40674-016-0050-y]
8. Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear Antibodies in Systemic Sclerosis: an Update. *Clin Rev Allergy Immunol*. 2020;58(1):40-51. [DOI:10.1007/s12016-018-8718-8] [PMID]
9. Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ. Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjogren's Syndrome: Analysis of the Sjogren's International Collaborative Clinical Alliance Cohort. *Arthritis Care Res (Hoboken)*. 2016;68(10):1554-9. [DOI:10.1002/acr.22859] [PMID] [PMCID]
10. Codullo V, Bardoni A, Salvini R, Montecucco C. Antinuclear antibodies in systemic sclerosis. *Future Rheumatology*. 2006;1(3):365-71. [DOI:10.2217/17460816.1.3.365]
11. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. *Medicine (Baltimore)*. 2002;81(2):139-53. [DOI:10.1097/00005792-200203000-00004] [PMID]
12. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. *Annu Rev Pathol*. 2011;6(1):509-37. [DOI:10.1146/annurev-pathol-011110-130312] [PMID]
13. Zanatta E, Codullo V, Avouac J, Allanore Y. Systemic sclerosis: Recent insight in clinical management. *Joint Bone Spine*. 2020;87(4):293-9. [DOI:10.1016/j.jbspin.2019.09.015] [PMID]
14. Jagadish R, Mehta DS, Jagadish P. Oral and periodontal manifestations associated with systemic sclerosis: A case series and review. *J*

Statistical Analysis: Najafi S., Hadadi M.

Draft of Manuscript: Mardani M.

Revisions: Motamedifar M., Nazarinia M.A.

Final Version of Manuscript: All authors approved the final version of the manuscript.

## Funding

This study was financially supported by the Vice-chancellor of Research at Shiraz University of Medical Sciences, Shiraz, Iran (grant no. 1399.01.03.22537).

## Conflict of Interest

The authors declare no conflict of interest.

- Indian Soc Periodontol. 2012;16(2):271-4. [DOI:10.4103/0972-124X.99275] [PMID] [PMCID]
15. Veale BJ, Jablonski RY, Frech TM, Pauling JD. Orofacial manifestations of systemic sclerosis. *Br Dent J*. 2016;221(6):305-10. [DOI:10.1038/sj.bdj.2016.678] [PMID]
  16. Bajraktari IH, Kryeziu A, Sherifi F, Bajraktari H, Lahu A, Bajraktari G. Oral manifestations of Systemic Sclerosis and Correlation with anti-Topoisomerase I Antibodies (SCL-70). *Med Arch*. 2015;69(3):153-6. [DOI:10.5455/medarh.2015.69.153-156] [PMID] [PMCID]
  17. Crincoli V, Fatone L, Fanelli M, Rotolo RP, Chiala A, Favia G, et al. Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. *Int J Mol Sci*. 2016;17(7):1189-201. [DOI:10.3390/ijms17071189] [PMID] [PMCID]
  18. Simonova MV, Grinin VM, Nasonova VA, Robustova TG. [Clinical factors essential for dental caries intensity in rheumatic patients]. *Stomatologiya (Mosk)*. 2002;81(2):15-9.
  19. Chu CH, Yeung CM, Lai IA, Leung WK, Mok MY. Oral health of Chinese people with systemic sclerosis. *Clin Oral Investig*. 2011;15(6):931-9. [DOI:10.1007/s00784-010-0472-0] [PMID] [PMCID]
  20. Lemos JA, Palmer SR, Zeng L, Wen ZT, Kajfasz JK, Freires IA, et al. The Biology of *Streptococcus mutans*. *Microbiol Spectr*. 2019;7(1):435-48. [DOI:10.1128/microbiolspec.GPP3-0051-2018] [PMID] [PMCID]
  21. Lemos JA, Quivey RG, Koo H, Abranches J. *Streptococcus mutans*: a new Gram-positive paradigm? *Microbiology (Reading)*. 2013;159(Pt 3):436-45. [DOI:10.1099/mic.0.066134-0] [PMID] [PMCID]
  22. Parisotto TM, Steiner-Oliveira C, Duque C, Peres RC, Rodrigues LK, Nobre-dos-Santos M. Relationship among microbiological composition and presence of dental plaque, sugar exposure, social factors and different stages of early childhood caries. *Arch Oral Biol*. 2010;55(5):365-73. [DOI:10.1016/j.archoralbio.2010.03.005] [PMID]
  23. Zhang G, Lu M, Liu R, Tian Y, Vu VH, Li Y, et al. Inhibition of *Streptococcus mutans* Biofilm Formation and Virulence by *Lactobacillus plantarum* K41 Isolated From Traditional Sichuan Pickles. *Front Microbiol*. 2020;11:774. [DOI:10.3389/fmicb.2020.00774] [PMID] [PMCID]
  24. Schwendicke F, Korte F, Dorfer CE, Kneist S, Fawzy El-Sayed K, Paris S. Inhibition of *Streptococcus mutans* Growth and Biofilm Formation by Probiotics in vitro. *Caries Res*. 2017;51(2):87-95. [DOI:10.1159/000452960] [PMID]
  25. Soderling EM, Marttinen AM, Haukioja AL. Probiotic lactobacilli interfere with *Streptococcus mutans* biofilm formation in vitro. *Curr Microbiol*. 2011;62(2):618-22. [DOI:10.1007/s00284-010-9752-9] [PMID]
  26. Pradeep K, Kuttappa MA, Prasana KR. Probiotics and oral health: an update. *SADJ*. 2014;69(1):20-4.
  27. Haukioja A. Probiotics and oral health. *Eur J Dent*. 2010;4(3):348-55. [DOI:10.1055/s-0039-1697851] [PMID] [PMCID]
  28. Lin X, Chen X, Chen Y, Jiang W, Chen H. The effect of five probiotic lactobacilli strains on the growth and biofilm formation of *Streptococcus mutans*. *Oral Dis*. 2015;21(1):e128-34. [DOI:10.1111/odi.12257]
  29. Zare Javid A, Amerian E, Basir L, Ekrami A, Haghighi Zadeh MH. Effects of short-term consumption of probiotic yogurt on *streptococcus mutans* and lactobacilli levels in 18-30 years old students with initial stages of dental caries in Ahvaz City. *Nutr Food Sci Res*. 2015;2(2):7-12.
  30. Li M, Zou Y, Jiang Q, Jiang L, Yu Q, Ding X, et al. A preliminary study of the oral microbiota in Chinese patients with Sjogren's syndrome. *Arch Oral Biol*. 2016;70(1):143-8. [DOI:10.1016/j.archoralbio.2016.06.016] [PMID]
  31. van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, et al. Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjogren's syndrome than underlying disease. *Ann Rheum Dis*. 2018;77(10):1542-4. [DOI:10.1136/annrheumdis-2018-213026] [PMID]
  32. Gomar-Vercher S, Simon-Soro A, Montiel-Company JM, Almerich-Silla JM, Mira A. Stimulated and unstimulated saliva samples have significantly different bacterial profiles. *PLoS One*. 2018;13(6):e0198021. [DOI:10.1371/journal.pone.0198021] [PMID] [PMCID]

33. Karaođlanođlu S, Akgül N, Akgül HM. The association between the DMFS index and levels of salivary Streptococcus mutans and lactobacilli of subjects living in Erzurum, Turkey. *Journal of Dental Sciences*. 2010;5(2):70-4. [DOI:10.1016/S1991-7902(10)60011-6]
34. Mortazavi H, Baharvand M, Movahhedian A, Mohammadi M, Khodadoust A. Xerostomia due to systemic disease: a review of 20 conditions and mechanisms. *Ann Med Health Sci Res*. 2014;4(4):503-10. [DOI:10.4103/2141-9248.139284] [PMID] [PMCID]
35. Muñoz C, Martínez A, Flores M, Catalán A. Relationship Between Xerostomia and Hyposalivation in Senior Chilean People. *Revista clínica de periodoncia, implantología y rehabilitación oral*. 2019;12(3):123-6. [DOI:10.4067/S0719-01072019000300123]
36. Parat K, Radic M, Perkovic D, Lukenda DB, Kaliterna DM. Reduced salivary flow and caries status are correlated with disease activity and severity in patients with diffuse cutaneous systemic sclerosis. *J Int Med Res*. 2020;48(10):300060520941375. [DOI:10.1177/0300060520941375] [PMID] [PMCID]
37. Mummolo S, Nota A, Albani F, Marchetti E, Gatto R, Marzo G, et al. Salivary levels of Streptococcus mutans and Lactobacilli and other salivary indices in patients wearing clear aligners versus fixed orthodontic appliances: An observational study. *PLoS One*. 2020;15(4):e0228798. [DOI:10.1371/journal.pone.0228798] [PMID] [PMCID]
38. Ravindran S, Chaudhary M, Gawande M. Enumeration of Salivary Streptococci and Lactobacilli in Children with Differing Caries Experiences in a Rural Indian Population. *ISRN Plastic Surgery*. 2013;2013:1-6. [DOI:10.5402/2013/476783]
39. Chokshi A, Mahesh P, Sharada P, Chokshi K, Anupriya S, Ashwini BK. A correlative study of the levels of salivary Streptococcus mutans, lactobacilli and Actinomyces with dental caries experience in subjects with mixed and permanent dentition. *J Oral Maxillofac Pathol*. 2016;20(1):25-8. [DOI:10.4103/0973-029X.180916] [PMID] [PMCID]
40. Sounah SA, Madfa AA. Correlation between dental caries experience and the level of Streptococcus mutans and lactobacilli in saliva and carious teeth in a Yemeni adult population. *BMC Res Notes*. 2020;13(1):112. [DOI:10.1186/s13104-020-04960-3] [PMID] [PMCID]
41. Hegde PP, Ashok Kumar BR, Ankola VA. Dental caries experience and salivary levels of Streptococcus mutans and Lactobacilli in 13-15 years old children of Belgaum city, Karnataka. *J Indian Soc Pedod Prev Dent*. 2005;23(1):23-6. [DOI:10.4103/0970-4388.16022] [PMID]
42. Mahler M, You D, Baron M, Taillefer SS, Hudson M, Canadian Scleroderma Research G, et al. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. *Clin Chim Acta*. 2011;412(21-22):1937-43. [DOI:10.1016/j.cca.2011.06.041] [PMID]